INTRODUCTION {#SEC1}
============

RNA interference (RNAi) is a cellular mechanism that regulates gene expression in a broad range of eukaryotes. In plants ([@B1]), insects ([@B2]), nematodes ([@B5],[@B6]), and fungi ([@B7]), the RNAi pathway is a crucial antiviral defense mechanism (reviewed in ([@B8],[@B9])). The antiviral potential of RNAi in vertebrates has only recently been demonstrated ([@B10],[@B11]). For insects, the antiviral RNAi pathway is most extensively studied in *Drosophila melanogaster*. The current model for antiviral RNAi in *Drosophila* is that virus-derived double-stranded RNA (dsRNA) is processed by Dicer-2 (Dcr-2) into viral small interfering RNA (vsiRNA) duplexes that associate with Argonaute-2 (AGO2) within the RNA-induced silencing complex (RISC) ([@B9]). One strand of the vsiRNA duplex is retained in RISC to guide the identification and AGO2-mediated cleavage (slicing) of complementary viral RNAs ([@B9]). The detection of vsiRNAs during infections of *Drosophila* cell lines and adult flies supports this model ([@B12],[@B13]). Moreover, the hypersensitivity of *Drosophila* RNAi pathway mutants to virus infections confirms the important role of RNAi in antiviral defense ([@B2],[@B14]).

Insect viruses encode viral suppressors of RNAi (VSRs) to counteract the antiviral RNAi pathway. For example, the Flock House virus (FHV) B2 and Drosophila C virus (DCV) 1A proteins bind and shield long dsRNA from Dcr-2 cleavage ([@B2],[@B5],[@B20],[@B21]). FHV B2 additionally binds siRNA duplexes, which inhibits their loading into RISC ([@B5],[@B20]). The 1A protein of Cricket paralysis virus (CrPV) and viral protein 1 (VP1) of Nora virus were recently shown to inhibit AGO2 Slicer activity ([@B22],[@B23]). In general, RNAi suppressor proteins of different virus families that target the same step in the RNAi pathway do not share sequence identity or structural conservation. Thus, insect viruses independently evolved a diverse set of RNAi antagonists that suppress the antiviral RNAi pathway by distinct mechanisms.

Mosquitoes are vectors for the transmission of arthropod-borne (arbo) viruses that can cause serious disease in humans, such as Dengue virus (DENV), West Nile virus (WNV) and Chikungunya virus ([@B24]). In addition, mosquitoes are hosts to a diverse array of mosquito-specific viruses that are not transmitted to vertebrates ([@B25]). These viruses do not cause human disease, but they are of interest with regard to human health. Mosquito-specific viruses infect mosquito species that act as important vectors for human arbovirus transmission. Activation and suppression of antiviral immune pathways by mosquito-specific viruses may affect the ability of a vector mosquito to transmit co-infecting arboviruses. Currently, however, not much is known about the interactions between the mosquito\'s immune system and the different classes of mosquito viruses.

As is observed in virus infections of *Drosophila*, vsiRNAs are detected in mosquitoes and mosquito cell lines infected with arboviruses and mosquito-specific viruses ([@B12],[@B13]). In addition, knockdown of RNAi pathway components in mosquitoes results in higher virus titers after infection with different arboviruses ([@B30]). These results show that, also in mosquitoes, the RNAi pathway serves as an important antiviral defense mechanism. Despite the antiviral activity of the mosquito RNAi pathway against a broad range of viruses, reports on VSR activity in viruses that infect mosquitoes are limited. VSRs have thus far only been identified in a few arboviruses from the genera *Alphanodavirus* (*Nodaviridae* family) and *Flavivirus* (*Flaviviridae* family) ([@B21],[@B33]). Whether mosquito-specific viruses suppress RNAi is unknown.

Nodamura virus (NoV), like FHV a member of the *Alphanodavirus* genus, was first isolated from *Culex tritaeniorhynchus* mosquitoes in Japan ([@B36]). Successful experimental infections in vertebrates, and the detection of neutralizing antibodies in pigs, suggest that NoV is a mosquito-transmitted arbovirus ([@B37]). The B2 protein of NoV, like FHV B2, inhibits RNAi by binding long dsRNA as well as siRNA duplexes ([@B21],[@B33]). More recently, the non-coding subgenomic flavivirus RNAs (sfRNAs) of WNV and DENV, two arboviruses from the *Flavivirus* genus, were shown to suppress RNAi ([@B34]). sfRNAs are abundantly produced during flavivirus infection and result from incomplete degradation of the genomic RNA ([@B38]). Probably because of their stem-loop structure, sfRNA molecules compete with Dicer substrates, thereby decreasing Dicer activity. DENV non-structural protein 4B (NS4B) was suggested to inhibit Dicer function through an undefined mechanism ([@B35]).

The identification and characterization of viral immune antagonists may provide important insights into the mechanisms, components and regulators of immune pathways. For example, the observation that two unrelated RNA viruses encode Slicer antagonists indicates that slicing of viral target RNAs is an important aspect of the antiviral RNAi response ([@B22],[@B23]). To begin to understand the diversity of RNAi-suppressive activities in mosquito viruses, we set out to study RNAi suppression by the mosquito-specific Culex Y virus (CYV). CYV is a bisegmented dsRNA virus from the *Entomobirnavirus* genus within the *Birnaviridae* family that was recently isolated from *Culex pipiens* mosquitoes in Germany ([@B27]). Isolation of the highly related Espirito Santo virus and Mosquito X virus in Brazil and China, respectively, indicates that these entomobirnaviruses are widely distributed in nature ([@B28],[@B29]).

Here, we demonstrate that CYV is a target of the *Culex* RNAi machinery. Furthermore, we show that CYV and Drosophila X virus (DXV), like CYV a member of the *Entomobirnavirus* genus, suppress the RNAi pathway during infection. The entomobirnavirus RNAi suppressor activity was mapped to VP3 and we show that the VP3 proteins can rescue the replication of a B2-deficient FHV RNA1 replicon. Finally, we demonstrate that the VP3 proteins bind long dsRNA as well as siRNAs and that they inhibit the production of siRNAs by Dcr-2. To our knowledge, we describe the first VSR of a mosquito-specific virus.

MATERIALS AND METHODS {#SEC2}
=====================

Cells and viruses {#SEC2-1}
-----------------

*Drosophila melanogaster* S2, *Culex quinquefasciatus* Hsu and *Culex tarsalis* CT cells were cultured in Schneider\'s *Drosophila* medium (Life Technologies) at 25°C (S2 cells) or 28°C (Hsu and CT cells). The medium was supplemented with 10% heat-inactivated fetal bovine serum (FBS; PAA Laboratories), 50 U/ml penicillin and 50 μg/ml streptomycin (pen/strep; Life Technologies). *Aedes albopictus* U4.4 cells were maintained at 28°C in Leibovitz\'s L-15 medium (Life Technologies) supplemented with 10% heat-inactivated FBS, 2% tryptose phosphate broth (Sigma-Aldrich), 1× MEM non-essential amino acids (Life Technologies) and pen/strep. CYV and DXV were propagated in S2 cells.

Plasmids, radioactively-labeled probes, recombinant proteins and western blot analysis {#SEC2-2}
--------------------------------------------------------------------------------------

The cloning and origin of plasmids, the production of radioactively-labeled probes, the purification of recombinant proteins and western blot analysis are described in the Supplementary Data.

Massive parallel sequencing of small RNAs {#SEC2-3}
-----------------------------------------

RNA was isolated from CYV-infected CT cells at 3 days post-infection using Isol-RNA Lysis Reagent (5 PRIME) and 30 μg of the RNA was separated on a 15% polyacrylamide/7M urea/0.5× TBE gel. The 19- to 33-nt small RNA fraction was cut from gel using ^32^P end-labeled RNA oligos as size markers. The RNA was eluted in 0.3 M of NaOAc, precipitated in 100% EtOH and dissolved in 10 μl of H~2~O. The small RNA library was prepared with the TruSeq Small RNA Sample Preparation Kit (Illumina) according to the manufacturer\'s instructions. After amplification, the library was separated on a 6% polyacrylamide/1× TBE gel. The PCR product corresponding to the amplified small RNAs was cut from gel, eluted in 0.3 M of NaOAc, precipitated in 100% EtOH in the presence of 20 μg of glycogen and reconstituted in 10 μl of 10 mM Tris-HCl. The library was sequenced on an Illumina HiSeq 2500 by Baseclear ([www.baseclear.nl](http://www.baseclear.nl)). FASTQ sequence reads were generated with the Illumina Casava pipeline (version 1.8.3) and initial quality assessment was performed by Baseclear using in-house scripts and the FASTQC quality control tool (version 0.10.0). FASTQ sequence reads that passed this quality control were deposited in the Sequence Read Archive (SRA) under accession number SRP041409.

The sequence data were analyzed with Galaxy ([@B39]). Sequence reads were clipped from the adapter sequence (TruSeq 3′ adapter index \#8) and mapped with Bowtie (version 1.1.2) ([@B40]) to the CYV reference genome (GenBank accession numbers: JQ659254 and JQ659255 for genome segments A and B, respectively). A size profile of the viral small RNAs was obtained from all reads that mapped to the CYV genome with a maximum of one mismatch. The 5′ ends of the 21-nt CYV-mapping reads were plotted onto the viral genome to analyze the genome distribution of the vsiRNAs.

RNAi reporter assays {#SEC2-4}
--------------------

RNAi reporter assays in S2 cells were performed as described previously ([@B41]). In dsRNA-induced RNAi reporter assays with individual proteins, S2 cells in 96-well plates were transfected with 12.5 ng of pMT-FLuc, 3 ng of pMT-RLuc and 50 ng of an expression plasmid for one of the viral proteins using Effectene Transfection Reagent (QIAGEN). Two days after transfection, 1.4 ng/μl of dsRNA was added to the culture supernatant. Expression of the luciferase reporters was induced the same day with 0.5 mM of CuSO~4~. Luciferase activities were measured the following day with the Dual-Luciferase Reporter Assay System (Promega). The siRNA-induced RNAi reporter assays with individual proteins were performed as two variants. One of these variants was identical to the dsRNA-induced RNAi reporter assay, except that dsRNA feeding was omitted and siRNAs (2 pmol) were co-transfected with the plasmids. In the other variant, S2 cells in 24-well plates were transfected with 100 ng of pCoBlast (Life Technologies) and 300 ng of an expression plasmid for one of the viral proteins. Two days after transfection, the cells were transferred to 96-well plates and the culture medium was supplemented with 25 μg/ml of blasticidin S (Life Technologies) to select for cells that express the viral proteins. The cells were transfected the following day with 12.5 ng of pMT-FLuc, 3 ng of pMT-RLuc, 2 pmol of siRNAs and 50 ng of a carrier plasmid. The reporters were induced the next day and luciferase activities were measured one day after induction. In RNAi reporter assays with infected cells, mock- and CYV-infected S2 cells in 96-well plates were transfected 3 days post-infection with 12.5 ng of pMT-FLuc, 3 ng of pMT-RLuc and either 10 ng of dsRNA or 2 pmol of siRNAs. Expression of the luciferase reporters was induced the same day and luciferase activities were measured 4 days post-infection. RNAi reporter assays with DXV-infected S2 cells were performed in a similar fashion, except that transfection and induction were performed at 6 h and 1 day post-infection, respectively. Luciferase activities were measured 2 days post-infection.

For RNAi reporter assays in CT cells, mock- and CYV-infected CT cells in 24-well plates were transfected 2 days post-infection with 250 ng of pAc-FLuc, 250 ng of pAc-RLuc and 10 ng of dsRNA using X-tremeGENE HP DNA Transfection Reagent (Roche). Luciferase activities were measured 2 days post-infection.

FHV RNA1 replicon assay {#SEC2-5}
-----------------------

S2 cells in a 24-well plate were transfected with 100 ng of the wild-type or ΔB2 FHV RNA1 replicons and 300 ng of an expression plasmid for one of the viral proteins using Effectene Transfection Reagent. Transcription of the FHV RNA1 replicons was induced two days after transfection by the addition of 0.5 mM of CuSO~4~ to the culture supernatant. The next day, RNA was isolated from the cells using Isol-RNA Lysis Reagent. The RNA was treated with DNase I (Life Technologies) and converted to cDNA using TaqMan Reverse Transcription Reagents (Life Technologies) and either FHV RNA1-specific primer T7-FHV-RNA1-R1 or RpL32-specific primer RpL32-R1 (Supplementary Table S1). The cDNA samples were then used in quantitative PCRs (qPCRs) on a LightCycler 480 (Roche) using GoTaq qPCR Master Mix (Promega) and either primers T7-F1 and FHV-RNA1-F3 (FHV RNA1 qPCR) or primers RpL32-R1 and RpL32-F1 (RpL32 qPCR) (Supplementary Table S1). The FHV RNA1 data were normalized to RpL32.

Dicer assays, Slicer assays and electrophoretic mobility shift assays (EMSAs) {#SEC2-6}
-----------------------------------------------------------------------------

Dicer assays, Slicer assays and EMSAs with purified recombinant proteins and radioactively-labeled probes were done essentially as described previously ([@B2],[@B23],[@B42]). Dicer assays were performed in 12-μl reactions with recombinant proteins, 4 μl of cell extract and 5 ng of radioactively-labeled 126-nt dsRNA. For Dicer assays in mock- and CYV-infected cell extracts, recombinant proteins were omitted from the reaction. Dicer assays in S2 cell extracts were incubated for 3 h at 25°C and those in U4.4, CT and Hsu cell extracts at 28°C. The reactions were treated with proteinase K (Life Technologies), extracted with phenol/chloroform, precipitated and analyzed on 12% denaturing polyacrylamide gels.

Slicer assays were done in 11-μl reactions that contained 5 μl of *D. melanogaster* embryo lysate and 50 nM of siRNAs. The siRNA duplexes were first incubated in the embryo lysates for 30 min at 25°C to allow assembly of mature RISC. Recombinant proteins were then added and the incubation was continued for another 30 min before the reactions were supplemented with the radioactive 5′ cap-labeled 492-bp target RNA. The reactions were incubated for an additional 2 h at 25°C before they were treated with proteinase K, extracted with phenol/chloroform, precipitated and analyzed on an 8% denaturing polyacrylamide gel.

EMSAs were performed in 16-μl reactions with recombinant proteins and either 5 ng of radioactively-labeled 126-nt dsRNA or 1 nM of radioactively-labeled 21-nt siRNA, 21-nt dsRNA, 19-nt dsRNA, 23-nt microRNA (miRNA) or 21-nt dsDNA duplexes. The reactions were incubated for 1 h at room temperature and analyzed on 6% (126-nt dsRNA) and 8% (small RNA and DNA duplexes) native polyacrylamide gels.

Dicer assays, Slicer assays and EMSAs were visualized by autoradiography using KODAK BioMax XAR films. To quantify the fraction bound probe in the EMSAs, the radioactive signals were captured with a Molecular Imager FX (Bio-Rad) and quantified with ImageJ (version 1.47k) ([@B43]).

Statistics {#SEC2-7}
----------

IBM SPSS Statistics (version 20) was used to statistically analyze the data. Statistical significance was addressed by applying an unpaired *t*-test or, in the case of multiple comparisons, a one-way ANOVA followed by a Dunnett\'s *post hoc* test.

RESULTS {#SEC3}
=======

CYV is a target of the Culex RNAi machinery {#SEC3-1}
-------------------------------------------

The identification of vsiRNAs in infections with DXV, Drosophila birnavirus and Mosquito X virus as well as the enhanced sensitivity of *R2D2* and *AGO2* mutant flies to DXV infection indicates that entomobirnaviruses are a target of the antiviral RNAi machinery in insects ([@B14],[@B29],[@B44],[@B45]). To investigate whether the *Culex* RNAi machinery targets CYV, we first analyzed whether CYV efficiently replicates in *C. quinquefasciatus* Hsu and *C. tarsalis* CT cells. Since Hsu cells were resistant to CYV (data not shown), we performed massive parallel sequencing of the small RNAs in CYV-infected CT cells. The small RNAs were mapped to the viral genome allowing one mismatch during alignment to account for genome variants that result from the relatively high error rates generally observed for viral RNA-dependent RNA polymerases. We detected 10 260 120 small RNAs that mapped to the viral genome. These viral small RNAs were almost exclusively 21 nt in length (Figure [1A](#F1){ref-type="fig"}), a hallmark of siRNAs that are generated by Dcr-2. The majority of the 21-nt vsiRNAs (9 001 430 in total; 6 997 378 and 2 004 052 for segments A and B, respectively) mapped across the entire length of the viral genome (Figure [1B](#F1){ref-type="fig"}). In addition, we noted a clear vsiRNA hotspot on the 3′ end of the (−) strand of both genome segments (Figure [1B](#F1){ref-type="fig"}). Overall, however, the vsiRNAs did not display a clear strand bias, as they mapped in similar numbers to the sense strand (46% for segment A and 47% for segment B) and antisense strand (54% for segment A and 53% for segment B) (Figure [1B](#F1){ref-type="fig"}). These results indicate that CYV is exposed to an RNAi response in *Culex* cells and they suggest that the CYV dsRNA genome is the major Dcr-2 substrate for vsiRNA production. Similar results were obtained when restricting the analyses to the 9 875 389 small RNAs that mapped to the viral genome without mismatches (data not shown).

![CYV is targeted by the *Culex* RNAi machinery. (**A**) Size profile of viral small RNAs in CYV-infected CT cells. The small RNAs were mapped to the CYV genome allowing one mismatch. (**B**) Distribution of the vsiRNAs over the CYV genome. The 21-nt vsiRNAs in CYV-infected CT cells were aligned to CYV genome segments A (upper panel) and B (lower panel). Small RNAs that map to the (+) strand of the viral genome are shown in red and those that map to the (−) strand in blue.](gku528fig1){#F1}

The CYV VP3 protein suppresses RNAi {#SEC3-2}
-----------------------------------

Since CYV is a target of the antiviral RNAi machinery in *Culex*, we deemed it likely that the virus would encode a VSR. We therefore used well-established reporter assays to determine whether CYV counteracts RNAi ([@B41]). In these assays, the effect of virus infection or expression of individual viral proteins on RNAi-mediated silencing of a firefly luciferase (FLuc) reporter is monitored. We first determined whether RNAi is suppressed in cells that are infected with CYV. To this end, we measured luciferase activities in mock- and CYV-infected cells that were co-transfected with the FLuc reporter plasmid and 113-nt *in vitro* transcribed FLuc dsRNA. A *Renilla* luciferase (RLuc) reporter plasmid was included as a normalization control. As expected, in mock-infected *Drosophila* S2 cells, the FLuc reporter was efficiently silenced (∼600-fold) by dsRNA treatment (Figure [2A](#F2){ref-type="fig"}, left panel). However, dsRNA-mediated silencing of the FLuc reporter was strongly suppressed (to ∼6-fold; *P* = 0.002) in CYV-infected S2 cells (Figure [2A](#F2){ref-type="fig"}, left panel). A comparable reduction of FLuc silencing (from ∼300-fold to ∼20-fold; *P* \< 0.001) was observed in CYV-infected *Culex* CT cells (Figure [2A](#F2){ref-type="fig"}, right panel). CYV infection also suppressed silencing of the FLuc reporter (from ∼15-fold to ∼3-fold; *P* = 0.025) when we induced RNAi with 21-nt synthetic siRNA duplexes (Figure [2B](#F2){ref-type="fig"}). These data show that CYV infection inhibits RNAi induced by dsRNA as well as siRNAs.

![RNAi is suppressed during CYV infection. (**A**) dsRNA-induced RNAi reporter assays in infected *Drosophila* S2 (left panel) and *Culex* CT (right panel) cells. Firefly (FLuc) and *Renilla* (RLuc) luciferase expression plasmids were transfected together with non-specific control (dsCtrl) or FLuc (dsFLuc) dsRNA into mock- and CYV-infected cells. Luciferase activities were measured and FLuc counts were normalized to RLuc counts. The data are presented as fold silencing relative to dsCtrl. (**B**) siRNA-induced RNAi reporter assay in infected S2 cells. The experiment was performed as in (A), except that RNAi was induced by co-transfection of non-specific control (siCtrl) or FLuc (siFLuc) siRNAs along with the luciferase expression plasmids. The data are presented as fold silencing relative to siCtrl. Bars and error bars in all panels represent the mean and standard deviation of three independent samples.](gku528fig2){#F2}

To identify the viral proteins responsible for CYV-mediated RNAi suppression, we generated expression constructs for the five proteins (VP1 to VP5) that are predicted to be encoded by the CYV genome (Figure [3A](#F3){ref-type="fig"}). Expression of all five proteins in transfected cells was confirmed by western blot analysis (Figure [3B](#F3){ref-type="fig"}). We then tested the individual viral proteins for VSR activity in our RNAi reporter assays. Cells were co-transfected with the FLuc and RLuc reporter plasmids and an expression plasmid for one of the viral proteins. The FLuc reporter was silenced by dsRNA feeding two days after transfection to allow expression of the viral proteins before the induction of RNAi. Of the five viral proteins, only VP3 suppressed silencing of the FLuc reporter (from ∼15-fold to background levels; *P* \< 0.001) to a similar extent as the positive control CrPV 1A ([@B22]) (Figure [3C](#F3){ref-type="fig"}). However, VP3 did not inhibit silencing of the FLuc reporter when RNAi was induced by co-transfection of siRNAs along with the luciferase and VP3 expression plasmids (Figure [3D](#F3){ref-type="fig"}). This is in contrast to the AGO2 antagonists Nora virus VP1 (*P* = 0.002) and CrPV 1A that effectively suppress siRNA-induced RNAi in reporter assays (Figure [3D](#F3){ref-type="fig"} and ([@B22],[@B23])). The inability of VP3 to suppress siRNA-induced RNAi under these conditions seems at odds with the reduced efficiency of siRNA-induced RNAi in CYV-infected cells (Figure [2B](#F2){ref-type="fig"}). However, in Figure [2B](#F2){ref-type="fig"}, the cells were infected three days prior to transfection of the siRNAs and reporter plasmids, whereas in Figure [3D](#F3){ref-type="fig"}, the siRNAs were co-transfected along with the luciferase and VP3 expression plasmids. Most likely, the siRNAs are incorporated into RISC before VP3 is expressed at sufficiently high levels in the latter case. Indeed, VP3 was able to suppress silencing of the FLuc reporter (from ∼27-fold to ∼13-fold; *P* \< 0.001) when the VP3 expression plasmid was transfected three days before transfection of the siRNAs and reporter plasmids (Figure [3E](#F3){ref-type="fig"}). These data suggest that VP3 suppresses the RNAi pathway at a step that precedes target cleavage by AGO2.

![CYV VP3 suppresses RNAi. (**A**) Schematic representation of the bisegmented dsRNA genome of CYV. Genome segment A encodes a polyprotein precursor of pVP2 (capsid precursor), VP4 (protease) and VP3 (ribonucleoprotein). A VP5 protein, homologous to DXV VP5, might be expressed from the −1 reading frame. Unlike DXV VP5, which initiates from a canonical AUG codon, expression of CYV VP5 would require initiation from a non-AUG codon. To ensure efficient expression, we introduced an AUG start codon in the CYV VP5 expression plasmid. Genome segment B encodes the RNA-dependent RNA polymerase VP1. (**B**) Western blot analysis of CYV protein expression. S2 cells were transfected with a plasmid encoding one of the CYV proteins (VP1 to VP5) fused to the V5-epitope tag and protein expression was analyzed by western blot using anti-V5 antibodies. (**C**) dsRNA-induced RNAi reporter assay in S2 cells. Firefly (FLuc) and *Renilla* (RLuc) luciferase expression plasmids were transfected into the cells together with an empty vector control (Vector) or a plasmid encoding one of the CYV proteins (VP1 to VP5). An expression plasmid for CrPV 1A was used as positive control. Two days after transfection, the cells were soaked in medium containing non-specific control (dsCtrl) or FLuc (dsFLuc) dsRNA. Luciferase activities were measured and FLuc counts were normalized to RLuc counts. The data are presented as fold silencing relative to dsCtrl. (**D**) and (**E**) siRNA-induced RNAi reporter assays in S2 cells. The experiments were done as in (C), except that RNAi was induced with non-specific control (siCtrl) or FLuc (siFLuc) siRNAs. In (D), the siRNAs were co-transfected along with the expression plasmids for the luciferases and the viral proteins, whereas in (E), the siRNAs and luciferase expression plasmids were co-transfected three days after transfection of the plasmids that encode the viral proteins. An expression plasmid for Nora virus VP1 (Nora VP1) was used as positive control. The data are presented as fold silencing relative to siCtrl. Bars and error bars in (C) to (E) represent the mean and standard deviation of three independent samples.](gku528fig3){#F3}

The RNAi pathway shares basic features with the miRNA pathway. Both pathways depend on Dicer proteins for the generation of small RNAs that guide the recognition and silencing of complementary RNAs by Argonaute proteins. The Dicer and Argonaute proteins in the RNAi and miRNA pathways are, however, different. The RNAi pathway depends on Dcr-2 and AGO2 for small RNA biogenesis and function, whereas the miRNA pathway predominantly depends on Dcr-1 and AGO1. We observed that CYV VP3 did not interfere with miRNA biogenesis and function (see Supplementary Data), indicating that VP3 specifically inhibits the RNAi pathway.

The VSR activity of VP3 is conserved in DXV {#SEC3-3}
-------------------------------------------

Having identified CYV VP3 as a suppressor of RNAi, we analyzed whether the VSR activity of this protein is conserved in DXV, an entomobirnavirus that infects *Drosophila*. To this end, we first studied RNAi suppression in DXV-infected cells. As observed for CYV, dsRNA-mediated silencing of the FLuc reporter was strongly suppressed (from ∼1300-fold to ∼150-fold; *P* = 0.005) in S2 cells infected with DXV (Figure [4A](#F4){ref-type="fig"}). We then tested the DXV VP3 protein for VSR activity. DXV VP3 suppressed silencing of the FLuc reporter (from ∼15-fold to background levels; *P* \< 0.001) when RNAi was induced by dsRNA feeding two days after transfection of the luciferase and VP3 expression plasmids (Figure [4B](#F4){ref-type="fig"}). In addition, DXV VP3 suppressed silencing of the FLuc reporter (from ∼23-fold to ∼9-fold; *P* \< 0.001) when we induced RNAi by co-transfection of siRNAs along with the luciferase and VP3 expression plasmids (Figure [4C](#F4){ref-type="fig"}), and (from ∼19-fold to ∼3-fold; *P* \< 0.001) when the siRNAs and reporter plasmids were transfected three days after transfection of the VP3 expression plasmid (Figure [4D](#F4){ref-type="fig"}). These results indicate that the VSR activity of VP3 is conserved during entomobirnavirus evolution.

![DXV VP3 suppresses RNAi. (**A**) dsRNA-induced RNAi reporter assay in infected S2 cells. The assay was performed with DXV as described for CYV in the legend to Figure [2A](#F2){ref-type="fig"}. (**B**) dsRNA-induced and (**C**) and (**D**) siRNA-induced RNAi reporter assays in S2 cells. The experiments were done as described in the legends to Figure [3C](#F3){ref-type="fig"}, D and E, respectively, but with a plasmid encoding DXV VP3. An expression plasmid for Nora virus VP1 (Nora VP1) was used as positive control. Bars and error bars in all panels represent the mean and standard deviation of three independent samples.](gku528fig4){#F4}

CYV and DXV VP3 can functionally replace FHV B2 {#SEC3-4}
-----------------------------------------------

Our data indicate that the CYV and DXV VP3 proteins are functional RNAi suppressors. Reverse genetics systems to engineer entomobirnaviruses are not yet available, precluding us to study the importance of VP3\'s VSR activity in an authentic infection. As an alternative, we tested whether the entomobirnavirus VP3 proteins can functionally replace B2, the well-established VSR of FHV ([@B5],[@B20],[@B21],[@B46]). The bisegmented FHV genome consists of genomic RNA1 and RNA2, which encode the RNA-dependent RNA polymerase (protein A) and capsid proteins, respectively. In addition to encoding the RNA-dependent RNA polymerase, RNA1 gives rise to subgenomic RNA3, which encodes the RNAi suppressor protein B2. FHV RNA1 can replicate autonomously, but its replication in RNAi competent insect cells is severely restricted in the absence of B2 ([@B4],[@B46]). The replication defect of B2-deficient FHV RNA1 is attributed to its inability to suppress the antiviral RNAi response, since its replication is restored by suppression of the RNAi pathway ([@B4],[@B46]).

We used an FHV RNA1ΔB2 replicon to determine whether the CYV and DXV VP3 proteins can rescue its replication. This FHV RNA1ΔB2 replicon contains two point mutations in the B2 coding region (Figure [5A](#F5){ref-type="fig"}). These point mutations disrupt B2, but they do not affect the amino acid sequence of the RNA-dependent RNA polymerase ([@B47]). We co-transfected cells with the FHV RNA1ΔB2 replicon and one of the VP3 expression plasmids and monitored RNA1 accumulation. As predicted, FHV RNA1ΔB2 was severely impaired when compared to wild-type FHV RNA1. The RNA1 levels of the B2-deficient replicon only reached 0.15% of those of the wild-type replicon, a difference of ∼700-fold. However, replication of the B2-deficient replicon was enhanced in the presence of our positive control Nora virus VP1 ([@B23]) (∼100-fold; to 15% of the wild-type replicon; *P* = 0.041), and in the presence of either CYV or DXV VP3 (∼200-fold; to 34% of the wild-type replicon; *P* \< 0.001 for both) (Figure [5B](#F5){ref-type="fig"}). These results show that entomobirnavirus VP3 proteins can functionally replace the VSR of FHV.

![CYV and DXV VP3 rescue replication of a B2-deficient FHV RNA1 replicon. (**A**) Schematic representations of FHV RNA1 and FHV RNA1ΔB2. The replicons are launched from a copper-inducible metallothionein promoter (P~MT~). Their 3′ end is defined by a Hepatitis delta virus (HδV) ribozyme. Mutations in the B2 coding sequence are indicated by arrow heads. Mutation 1 (T2739C; with respect to the FHV RNA1 sequence; GenBank accession number: X77156.1) disrupts the AUG start codon and mutation 2 (C2910A) introduces a premature UAA stop codon. RdRp, RNA-dependent RNA polymerase (**B**) FHV RNA1 replicon assay in S2 cells. The FHV RNA1ΔB2 replicon was transfected into the cells together with an empty vector control (Vector) or a plasmid encoding either CYV or DXV VP3. An expression plasmid for Nora virus VP1 (Nora VP1) was used as positive control. The wild-type FHV RNA1 replicon was transfected together with the empty vector control to indicate wild-type replication levels. FHV RNA1 replication levels were quantified by qPCR and normalized to RpL32. The data are presented as fold change relative to FHV RNA1ΔB2 co-transfected with the empty vector control. Bars and error bars in (B) represent the mean and standard deviation of three independent samples.](gku528fig5){#F5}

CYV and DXV VP3 inhibit dicing of dsRNA {#SEC3-5}
---------------------------------------

VSRs of different viruses may target different aspects of the RNAi machinery, such as Dcr-2-mediated cleavage of dsRNA and slicing of target RNAs by AGO2. To characterize the VSR activity of CYV and DXV VP3 in more detail, we performed a series of biochemical assays using maltose-binding protein (MBP)-tagged recombinant proteins purified from *Escherichia coli*. We first tested whether the recombinant VP3 proteins interfere with dicing of dsRNA, the initiation phase of the RNAi pathway. We incubated radioactively-labeled 126-nt dsRNA in *D. melanogaster* S2, *A. albopictus* U4.4, *C. quinquefasciatus* Hsu and *C. tarsalis* CT cell extracts and monitored its processing into 21-nt siRNAs on denaturing polyacrylamide gels. The dsRNA was efficiently processed into siRNAs in extracts from all cell types (Figure [6A](#F6){ref-type="fig"}, lanes 10, 15, 20 and 25). Processing of the dsRNA was, however, inhibited in a dose-dependent manner by the VP3 proteins of both CYV (Figure [6A](#F6){ref-type="fig"}, lanes 6--8, 11--13, 16--18 and 21--23) and DXV (Figure [6A](#F6){ref-type="fig"}, lanes 3--5), and in the presence of DCV 1A (Figure [6A](#F6){ref-type="fig"}, lane 1), a VSR that is known to interact with dsRNA ([@B2]). As expected, MBP alone did not inhibit dsRNA processing (Figure [6A](#F6){ref-type="fig"}, lanes 9, 14, 19 and 24). These data indicate that the entomobirnavirus VP3 proteins interfere with siRNA production by Dcr-2. Importantly, inhibition of dsRNA cleavage into siRNAs was also observed in extracts from *Drosophila* S2 and *Culex* CT cells infected with CYV. The dsRNA was processed in extracts from mock-infected cells (Figure [6B](#F6){ref-type="fig"}, lanes 5 and 10), but no dsRNA processing was observed in extracts from CYV-infected cells (Figure [6B](#F6){ref-type="fig"}, lanes 1 and 6). Titration of CYV-infected cell extracts into mock-infected cell extracts abolished dsRNA processing (Figure [6B](#F6){ref-type="fig"}, lanes 2--4 and 7--9), which confirms the presence of a Dcr-2 inhibitor in CYV-infected cells.

![CYV and DXV VP3 inhibit Dicer, but not Slicer activity. (**A**) Dicer assays in extracts from *Drosophila* S2 (first panel), *Aedes* U4.4 (second panel), *Culex* Hsu (third panel) and *Culex* CT (fourth panel) cells. Radioactively-labeled 126-nt dsRNA was incubated in the extracts in the presence of MBP-tagged CYV or DXV VP3. Glutathione S-transferase (GST)-tagged DCV 1A served as positive control and MBP and GST alone as negative controls. Processing of the dsRNA into 21-nt siRNAs was monitored by denaturing polyacrylamide gel electrophoresis followed by autoradiography. Protein concentrations were as follows: 10-fold dilutions starting at 1 μM for CYV VP3 (lanes 6--8, 11--13, 16--18 and 21--23) and DXV VP3 (lanes 3--5); 1 μM for MBP (lanes 9, 14, 19 and 24); 0.5 μM for DCV 1A (lane 1) and GST (lane 2). Reactions with buffer instead of recombinant protein (No protein; lanes 10, 15, 20 and 25) were used as controls for Dcr-2 activity. (**B**) Dicer assays in extracts from infected S2 (left panel) and CT (right panel) cells. Radioactively-labeled 126-nt dsRNA was incubated in mixtures of mock- and CYV-infected cell extracts. The production of siRNAs was monitored as in (A). Ratios of mock- to CYV-infected cell extracts were as follows: 4:0 (lanes 5 and 10); 3:1 (lanes 4 and 9); 2:2 (lanes 3 and 8); 1:3 (lanes 2 and 7); 0:4 (lanes 1 and 6). (**C**) Slicer assay in *Drosophila* embryo lysates. Embryo lysates were first incubated with non-specific control (siCtrl; lane 1) or firefly luciferase (siFLuc; lanes 2--12) siRNAs. MBP-tagged CYV or DXV VP3 was added after 30 min. MBP-tagged Nora virus VP1 (Nora VP1) served as positive control and MBP alone as negative control. After another 30 min, the radioactive 5′ cap-labeled FLuc target RNA was added. Cleavage of the target RNA was monitored by denaturing polyacrylamide gel electrophoresis followed by autoradiography. Protein concentrations were as follows: 2-fold dilutions starting at 1.2 μM for CYV VP3 (lanes 5--7) and DXV VP3 (lanes 8--10); 1.2 μM (lane 3) or 0.3 μM (lanes 4 and 12) for MBP; 0.3 μM for Nora VP1 (lane 11). Reactions with buffer instead of recombinant protein (lanes 1 and 2) were used as controls for Slicer activity.](gku528fig6){#F6}

We next tested whether the recombinant VP3 proteins are capable of interfering with slicing of target RNAs, the effector phase of the RNAi pathway. For this purpose, a radioactive 5′ cap-labeled target RNA, containing 492 nt of the FLuc coding sequence, was incubated in *D. melanogaster* embryo extracts in the presence of a FLuc-specific siRNA that triggers its cleavage. Cleavage of the target RNA results in the production of a 164-nt 5′ cleavage product that can be visualized on a denaturing polyacrylamide gel. As expected, cleavage of the target RNA was induced by the FLuc-specific siRNA (Figure [6C](#F6){ref-type="fig"}, lane 2), but not by a non-specific control siRNA (Figure [6C](#F6){ref-type="fig"}, lane 1). Neither MBP alone (Figure [6C](#F6){ref-type="fig"}, lanes 3, 4 and 12), nor the VP3 proteins of CYV (Figure [6C](#F6){ref-type="fig"}, lanes 5--7) or DXV (Figure [6C](#F6){ref-type="fig"}, lanes 8--10), inhibited target RNA cleavage. Complete inhibition of target RNA cleavage was, however, seen in the presence of the positive control Nora virus VP1 (Figure [6C](#F6){ref-type="fig"}, lane 11), an established VSR that interferes with the Slicer activity of AGO2 ([@B23]). These results demonstrate that the entomobirnavirus VP3 proteins do not interfere with target RNA cleavage by AGO2.

CYV and DXV VP3 possess dsRNA- and siRNA-binding activity {#SEC3-6}
---------------------------------------------------------

Many VSRs employ dsRNA binding as a mechanism to suppress RNAi ([@B8],[@B9]). The ability of the entomobirnavirus VP3 proteins to inhibit Dcr-2-mediated cleavage of dsRNA into siRNAs suggests a similar strategy of RNAi suppression. To study whether these proteins indeed possess dsRNA-binding activity, we performed EMSAs using the recombinant VP3 proteins and different radioactively-labeled probes.

First, we incubated 126-nt blunt dsRNA with serial dilutions of the recombinant VP3 proteins and resolved dsRNA--protein complexes on native polyacrylamide gels. As expected, incubation of dsRNA with MBP alone (Figure [7A](#F7){ref-type="fig"}, lane 15) did not alter its mobility when compared to the control reaction without recombinant protein (Figure [7A](#F7){ref-type="fig"}, lane 16). However, the mobility of the dsRNA was inhibited in a dose-dependent manner by the VP3 proteins of both CYV (Figure [7A](#F7){ref-type="fig"}, lanes 8--14) and DXV (Figure [7A](#F7){ref-type="fig"}, lanes 1--7). CYV and DXV VP3 displayed similar affinities for dsRNA, with dissociation constants of 115.6 ± 24.5 and 166.1 ± 33.2 nM, respectively (Figure [7A](#F7){ref-type="fig"}).

![CYV and DXV VP3 bind dsRNA independent of length. (**A**) EMSA with 126-nt dsRNA. Radioactively-labeled dsRNA was incubated with MBP-tagged CYV or DXV VP3. MBP alone served as negative control. The reactions were separated on a native polyacrylamide gel and visualized by autoradiography (left panel). The EMSA is representative for three independent experiments. The fraction bound probe was quantified for each protein concentration and used to calculate the *K*~d~ (right panels). Data points and error bars represent the mean and standard deviation of samples from the three independent experiments. Protein concentrations were as follows: 2-fold dilutions starting at 400 nM for CYV VP3 (lanes 8--14) and DXV VP3 (lanes 1--7); 400 nM for MBP (lane 15). A reaction with buffer instead of recombinant protein (No protein; lane 16) was used to mark the position of the free probe. (**B**) EMSA with 21-nt siRNAs. The assay was performed as in (A), but protein concentrations were as follows: 2-fold dilutions starting at 10 μM for CYV VP3 (lanes 8--14) and DXV VP3 (lanes 1--7); 10 μM for MBP (lane 15). (**C**) EMSAs with different RNA and DNA probes. In the 21-nt siRNA (first panel), 21-nt dsRNA (second panel) and 19-nt dsRNA (third panel) EMSAs, 4-fold dilutions starting at 10 μM of CYV VP3 (lanes 4--6, 12--14 and 20--22) and DXV VP3 (lanes 1--3, 9--11 and 17--19) were tested. In the 23-nt miRNA (fourth panel) and 21-nt dsDNA (fifth panel) EMSAs, CYV VP3 (lanes 26 and 30) and DXV VP3 (lanes 25 and 29) were analyzed at a concentration of 10 μM. The concentration of MBP (lanes 7, 15, 23, 27 and 31) was 10 μM in all EMSAs.](gku528fig7){#F7}

The dsRNA-binding activity of the entomobirnavirus VP3 proteins most likely suppresses RNAi by inhibiting dsRNA processing by Dcr-2. However, inhibition of siRNA production cannot fully explain the RNAi-suppressive activity of the VP3 proteins, since they suppressed siRNA-induced RNAi in our reporter assays (Figures [3E](#F3){ref-type="fig"} and [4D](#F4){ref-type="fig"}). This observation indicates that these proteins target additional steps of the RNAi pathway, such as loading of siRNAs into RISC or slicing of target RNAs by AGO2. Since our biochemical assays indicate that the VP3 proteins do not interfere with the AGO2 Slicer activity (Figure [6C](#F6){ref-type="fig"}), we tested whether these proteins have the potential to scavenge siRNAs to prevent their incorporation into RISC. To this end, we tested serial dilutions of the recombinant VP3 proteins in EMSAs with 21-nt siRNA duplexes containing 2-nt 3′ overhangs. When compared to the control reaction without recombinant protein (Figure [7B](#F7){ref-type="fig"}, lane 16), the mobility of the siRNAs was inhibited in a dose-dependent manner after incubation with the VP3 proteins of both CYV (Figure [7B](#F7){ref-type="fig"}, lanes 8--14) and DXV (Figure [7B](#F7){ref-type="fig"}, lanes 1--7), but not after incubation with MBP alone (Figure [7B](#F7){ref-type="fig"}, lane 15). As for long dsRNA, CYV and DXV VP3 showed similar affinities for siRNAs, with dissociation constants of 2.6 ± 1.4 and 5.9 ± 1.6 μM, respectively (Figure [7B](#F7){ref-type="fig"}). Interestingly, both proteins also bound 21- and 19-nt blunt dsRNA, but only showed weak binding to a 23-nt miRNA duplex (Figure [7C](#F7){ref-type="fig"}), consistent with the observation that VP3 does not inhibit the miRNA pathway (Supplementary Figure S1B). Binding was RNA-specific, as neither VP3 protein was able to interact with 21-nt blunt dsDNA (Figure [7C](#F7){ref-type="fig"}). Taken together, our data indicate that the entomobirnavirus VP3 proteins are RNAi suppressors that bind both long dsRNA as well as siRNAs. The dsRNA-binding activity of the VP3 proteins inhibits dsRNA processing into siRNAs and, presumably, loading of siRNAs into RISC.

DISCUSSION {#SEC4}
==========

Viruses employ many different strategies to suppress or evade the innate and adaptive immune responses of their hosts. In arthropods, RNAi has antiviral activity against all major classes of insect viruses, including (+) and (−) strand RNA, dsRNA and DNA viruses ([@B2],[@B14],[@B30]). Nevertheless, RNAi suppression has thus far not been detected in infections with dsRNA viruses. How widespread viral RNAi antagonism is among different classes of viruses remains unclear. Here, we show that the antiviral RNAi pathway is inhibited during infections with mosquito and *Drosophila* dsRNA viruses from the *Entomobirnavirus* genus (*Birnaviridae* family).

We mapped the VSR activity to VP3, a multifunctional protein that is involved in many aspects of the viral replication cycle. Most of our knowledge on the role of VP3 in birnavirus replication is derived from experiments with Infectious bursal disease virus (IBDV) and Infectious pancreatic necrosis virus (IPNV), members of the genera *Avibirnavirus* and *Aquabirnavirus*, respectively. The IBDV and IPNV VP3 proteins act as scaffolds during capsid assembly by interacting with the viral genome as well as with the viral VP1 (RNA-dependent RNA polymerase), pVP2 (capsid precursor) and other VP3 proteins ([@B48]). Our data reveal yet another function of VP3. We demonstrate that the entomobirnavirus VP3 proteins possess dsRNA- and siRNA-binding activity and inhibit Dcr-2-mediated siRNA production. Importantly, the entomobirnavirus VP3 proteins have no detectable homology to the VP3 proteins of viruses from the other *Birnaviridae* genera, nor could we identify known nucleic acid-binding motifs using online domain prediction programs. Whether entomobirnavirus VP3 has structural similarity to other dsRNA-binding proteins or whether it uses a novel protein fold for dsRNA binding is an open question for future investigation.

In principle, any dsRNA-binding protein has the potential to inhibit RNAi when overexpressed. Even a dsRNA-binding protein from *E. coli*, a species that is not targeted by an RNAi response, is able to suppress RNAi under overexpression conditions ([@B53]). It has been shown previously that the IBDV, IPNV and DXV VP3 proteins have the capacity to suppress RNAi ([@B54]). However, these studies were done in a heterologous system and the *in vivo* relevance in a relevant host remained unclear. Our study now provides evidence that both CYV and DXV infections suppress the RNAi response in insect cells and that their VP3 proteins are *bona fide* RNAi suppressors that rescue replication of a VSR-defective FHV RNA1 replicon.

dsRNA is an important activator of innate immune pathways, such as the interferon response in vertebrates and antiviral RNAi in invertebrates. To avoid recognition by the host\'s immune system, viruses have evolved different mechanisms to shield their dsRNA. The genomes of most dsRNA viruses, for example, are replicated in specialized viral cores that encapsulate the dsRNA genome throughout the viral replication cycle ([@B55]). These viral cores are common among dsRNA viruses, but they are absent from birnaviruses. Instead, studies with IBDV and IPNV have shown that birnaviruses form ribonucleoprotein (RNP) complexes consisting of the dsRNA genome and the VP1 and VP3 proteins ([@B56],[@B57]). Since VP3 binds homogenously along the dsRNA genome, the RNP complexes are thought to prevent the activation of cellular immune pathways. Our observation that the VP3 proteins of CYV and DXV inhibit RNAi by dsRNA binding supports this hypothesis. Entomobirnaviruses most likely form similar RNP complexes that shield the viral genome from the antiviral activity of the RNAi pathway. Nevertheless, we found that vsiRNAs, derived from the viral genome, are produced in CYV-infected cells. Moreover, vsiRNAs were previously detected in cells infected with DXV, Drosophila birnavirus and Mosquito X virus ([@B29],[@B44],[@B45]). These data imply that some of the entomobirnaviral dsRNA is accessible for Dcr-2. The observation that dsRNA viruses from the *Totiviridae* and *Reoviridae* families are also prone to an RNAi response shows that the protection of dsRNA by other dsRNA viruses is incomplete as well ([@B44],[@B58],[@B59]). By RNP complex formation, VP3 probably limits the accessibility of the viral genome for Dcr-2, but it cannot prevent that some viral dsRNA feeds into the RNAi pathway and is processed into siRNAs. These siRNAs may be loaded into RISC, where they guide cleavage of single-stranded viral transcripts, thereby adding another level of antiviral activity. However, we observed that the CYV and DXV VP3 proteins do not only bind long dsRNA, but also siRNA duplexes. These data suggest that VP3 does not merely protect the viral genome against Dcr-2, but that it also scavenges siRNAs to prevent their incorporation into RISC. Thus, entomobirnavirus VP3 proteins counteract multiple aspects of the antiviral RNAi machinery.

Complex interactions may be occurring between mosquito-specific viruses, pathogenic arboviruses and their mosquito hosts. For example, induction and suppression of antiviral pathways by mosquito-specific viruses may affect the transmission efficiency of co-infecting arboviruses. The characterization of RNAi antagonists in mosquito-specific viruses will thus contribute to our understanding of the factors that influence arbovirus transmission.

SUPPLEMENTARY DATA {#SEC5}
==================

[Supplementary Data](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gku528/-/DC1) are available at NAR Online.
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